A Systematic Review and Meta-Analysis of Symptoms of Anxiety, Depression, and Insomnia in Spain in the COVID-19 Crisis

Stephen X. Zhang 1*, Richard Z. Chen 2, Wen Xu 3*, Allen Yin 4*, Rebecca Kechen Dong 5*, Bryan Z. Chen 1, Andrew Yilong Delios 6, Saylor Miller 7, Roger S. McIntyre 8*, Wenping Ye 9 and Xue Wan 10*

Faculty of Professions, University of Adelaide, Adelaide, SA 5005, Australia; chenzbryan@gmail.com
Crescent Valley High School, Corvallis, OR 97330, USA; richardziychen@gmail.com
Nottingham University Business School China, University of Nottingham Ningbo China, Ningbo 315000, China; wen.xu@nottingham.edu.cn
School of Humanities, Southeast University, Nanjing 211189, China; allen-yin@hotmail.com
Business School, University of South Australia, Adelaide, SA 5001, Australia; rebecca.dong@unisa.edu.au
Department of Psychology, University of Adelaide, Adelaide, SA 5001, Australia; delios9580@gmail.com
College of Business, Oregon State University, Corvallis, OR 97330, USA; millesay@oregonstate.edu
Mood Symptoms Psychopharmacology Unit (MDPU), Department of Psychiatry, University of Toronto, Toronto, ON M5T 2S8, Canada; Roger.McIntyre@uhn.ca
Department of Business Administration, School of Management, Jinan University, Guangzhou 510632, China; yzq721@yahoo.net
School of Economics and Management, Tongji University, Shanghai 200092, China; wanxue@tongji.edu.cn
* Correspondence: stephen.x.zhang@gmail.com

Abstract: Background: General population, frontline healthcare workers (HCWs), and adult students in Spain are at risk of anxiety, depression, and insomnia symptoms during the COVID-19 crisis. A meta-analysis of the individual studies on these symptoms would provide systematic evidence to aid policymakers and researchers in focusing on prevalence, risk, and best interventions. Objective: This paper aims to be the first meta-analysis and systematic review to calculate the prevalence of anxiety, depression, and insomnia symptoms in Spain’s adult population (general population, frontline healthcare workers (HCWs), and adult students) during the Covid-19 epidemic. Method: Random-effect meta-analysis was used to estimate the prevalence of anxiety, depression, and insomnia. Results: The meta-analysis includes 28 studies with 38 individual samples in Spain. The pooled prevalence of anxiety symptoms in 22 studies comprising a sample population of 82,024 was 20% (95% CI: 15–25%), that of depression symptoms in 22 articles with a total sample comprising 82,890 individuals was 22% (95% CI: 18–28%), and that of insomnia symptoms in three articles with a sample population of 745 was 57% (95% CI: 48–66%). Conclusions: The accumulative evidence reveals that adults in Spain suffered higher prevalence rates of mental symptoms during the COVID-19 crisis, with a significantly higher rate relative to other countries such as China. Our synthesis also reveals a relative lack of studies on frontline and general HCWs in Spain.

Keywords: general population; frontline healthcare workers; anxiety; depression; meta-analysis

1. Introduction

Since COVID-19 was first reported on 17 November 2019, Spain, with its first case on 31 January 2020, is one of the countries in Europe most affected by infections, complications, and deaths. The COVID-19 crisis in Spain is particularly severe as a quarter of the population have been unable to isolate themselves according to public health recommendations [1]. Like most parts of the world, the COVID-19 pandemic has severely affected the Spanish population and has significantly altered the workplace and day-to-day activities. Disruptions such as social distancing laws, mandatory lockdowns, and a high
risk of infection can lead to psychological problems [2]. A survey study of 17 countries by Luo et al. [3] found that Spain had one of the highest prevalence rates of anxiety during the COVID-19 pandemic.

The prevalence of mental health disorders has become an important research topic globally with differences across regions [4]. For example, individual studies have reported the prevalence of mild anxiety symptoms in Spain range from 1.8% [5] to 58.6% [6], while mild depression symptoms have varied from 7.3% [5] to 46% [6]. Given the disparity, it is especially pertinent to conduct a meta-analysis to pool the prevalence rates from individual empirical studies to generate accumulative meta-analytical evidence. For instance, Chen et al. (2021) conducted a meta-analysis on the prevalence of mental health during the COVID-19 crisis in Africa and identified the extent and pattern of prevalence of mental health symptoms that carry crucial implications and impact future research, in order to enable evidence-based medicine in Africa [7]. Pappa et al. (2021) performed a systematic review and meta-analysis of mental health symptoms during the COVID-19 pandemic in Southeast Asia and found a significant proportion experienced at least mild to moderate levels of anxiety and depression, in order to inform targeted identification of mental health symptoms and facilitate appropriate resource planning and allocation in that region [8]. The meta-analytic evidence of depression and anxiety mental health in Eastern Europe during the COVID-19 pandemic helps to reveal the high prevalence rates of clinically significant symptoms [9] and calls for more effort to conduct such meta-analysis studies to assist evidence-based mental healthcare in other regions.

Answering this call and following such studies in other regions, this study aims to provide meta-analytical evidence on the prevalence rate of mental health symptoms in Spain to help with evidence-based decisions on the allocation of limited resources during the continuing COVID-19 crisis. This study conducts the first systematic review and meta-analysis of mental symptoms in Spain’s adult population by assessing the prevalence of anxiety, depression, and insomnia symptoms during the COVID-19 virus. The adult populations include the key populations that have been studied by individual papers, including healthcare workers, general adult population, and adult (university) students [10]. This systematic review and meta-analysis of empirical studies will help to guide mental health practitioners, policymakers, and researchers in their effort to better understand and address mental health in Spain.

2. Methods and Materials

We registered with the International Prospective Register of Systematic Reviews (PROSPERO: CRD42020224458) and used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 2020 to guide our search [11].

2.1. Data Sources and Search Strategy

This paper comes from a large project—a meta-analysis of mental health symptoms during COVID-19. We searched the following databases for studies that fit our criteria: PubMed, Embase, PsycINFO, and Web of Science from 1 February 2020 to 6 February 2021. To identify articles meeting the requirements, we searched specific titles and abstracts using the keywords in Table S1 with Boolean operators. We also searched the preprints at medRxiv.

2.2. Selection Criteria

The search included empirical studies that reported the prevalence of anxiety, depression, or insomnia symptoms among frontline HCWs, general HCWs, general adult populations, or adult (university) students in Spain. To be included, reports had to implement validated psychometric measures with outcomes reported in English.

We excluded studies that had populations of children, adolescents, or adult subpopulations (e.g., pregnant women). We also excluded non-original research or studies that were reviews, meta-analyses, qualitative and case studies, interviews, news reports, inter-
ventional studies, or articles without validated instruments or validated cutoff scores to identify prevalence.

A researcher (WX) contacted the authors of papers that lacked important information in several instances: (1) if they surveyed a population that included both targeted and excluded populations in such a way that we could not identify the prevalence rate for our desired population; (2) if the paper included primary data meeting our inclusion criteria, but did not report the prevalence; (3) if the paper reported the overall prevalence without specifying its cutoff point to determine whether it was mild above or moderate above; or (4) if the paper was missing, or unclear about, critical information such as respondent rate, data collection time, or female proportion rate.

2.3. Data Screening

To begin, we exported article information from various databases into Endnotes to remove duplicates and then imported them into Rayyan. Two researchers (BZC & AD) independently screened the titles and abstracts of all papers using our inclusion and exclusion criteria. Any conflicts were resolved by a third researcher (RKD).

2.4. Data Extraction

A well-developed coding protocol and coding book were developed based on previous studies [12]. All included articles from the screening were sent to two pairs of researchers who were assigned to thoroughly examine and extract important data into a coding book (WX & AY, BZC & AYD, RZC & SM). Using a coding procedure, the coders coded relevant information including author, title, country, start and end dates of data collection, study design, population, sample size, respondent rate, female proportion rate, age range and mean, outcome, outcome level, instruments, cutoff scores, and prevalence. We coded the severity prevalence as mild above, moderate above, and severe, if possible. Studies that reported mild, moderate, and severe prevalence were converted into mild above, moderate above, and severe prevalence. For studies that only reported the overall prevalence, we specified their severity if their cutoff points were reported.

Comments related to reasons for emailing and excluding papers were recorded. After both coders had independently coded their articles, they cross-checked their information. Different answers were conferred about and changed, and disagreements were settled by a third coder coding the article. The lead coder (RZC) double-checked important data including the population, sample size, mental health outcomes, outcome levels, instruments, and prevalence. Papers with unusual prevalence, cutoff scores, and numbers were double-checked for sensitivity analysis.

2.5. Assessment of Bias Risk

The Mixed Methods Appraisal Tool (MMAT) [13], a seven-question test that assesses the quality of research papers, was used for our meta-analysis. Pairs of coders individually coded these questions. Discrepancies were resolved through the lead coder (RZD). The quality scores of papers ranged from 0 to 7. Studies with a quality of above 6 were considered high, articles with a score of between 5 and 6 were classed as medium, and articles with a score of below 5 were considered low.

2.6. Data Analysis

Using Version 16.1 of Stata (Stata Corp LP, College Station, TX, USA), we conducted a random-effect meta-analysis to calculate the pooled prevalence from multiple studies using meta-prop. For each mental health symptom, we also conducted subgroup analyses by population (frontline HCWs, general population, and adult students), severity (above mild, above moderate, severe, and overall), and popular instrument (DASS-21 vs. GAD-7/PHQ-9).
2.7. Sensitivity Analysis

Research methodologists have found that the conventional funnel plots to assess biases in meta-analyses are inaccurate for proportion studies [14]. In meta-analysis of proportion studies, which was our approach, a Doi plot and the Luis Furuya-Kanamori (LFK) index represent the better approach for graphically representing publication bias—where a symmetrical triangle implies the absence of publication bias, while an asymmetrical triangle indicates possible publication bias [15]. The Doi plot and LFK index have higher sensitivity and power to detect publication bias than the funnel plot and Egger’s regression [16]. The LFK index provides a quantitative measure to assess the degree of asymmetry—a score within ±1 indicates ‘no asymmetry’, exceeds ±1 but is within ±2 indicates ‘minor asymmetry’, and exceeds ±2 indicates ‘major asymmetry’.

3. Results

3.1. Study Screening

Figure 1 illustrates the PRISMA flow chart for our search and data extraction process. We found 6949 citations from the selected database and other sources. After excluding 2729 entries that did not meet the inclusion criteria in the screening process, we extracted data from 684 citations based on their full text. After excluding 505 citations in the data extraction process, we coded 150 papers that included the necessary information to conduct the meta-analysis. In addition, we sent out two rounds of emails to the authors of 95 papers to request useful information. We received 75 responses. Among these responses, we received new prevalence data from eight out of the 29 studies that lacked prevalence data. Finally, we had 168 studies providing necessary information for meta-analysis, among which 28 articles had participants that were from Spain.

3.2. Study Characteristics

In total, this meta-analysis includes 38 samples from 28 studies with 86,323 participants from Spain [6,17–44], as summarized in Table 1. These articles were noted with an asterisk in the reference list. Among them, 30 samples (78.95%) were of general populations, three samples were of frontline HCWs (7.89%), and five (13.16%) were of adult students. Most studies were cross-sectional (85.71%), and four studies were longitudinal cohort studies (14.29%). Almost all studies were published (92.86%), while only 2 (7.14%) remained as preprints. The sample size of the 38 samples varies from 44 to 21,207, with a medium value of 1199. The participation rates varied from 20% to 98%, with a medium value of 70.3%. The female proportions among the 38 samples varied from 0% to 100% with a medium value of 70.25%. Table S2 reports the characteristics of each study.

3.3. Pooled Prevalence of Anxiety, Depression, and Insomnia

In Spain, 29 samples from 22 studies reported the prevalence of anxiety symptoms among 82,024 participants. The most common anxiety instruments used included the Depression, Anxiety and Stress Scale—21 Items (DASS-21) (54.5%) and the Generalized Anxiety Symptoms 7-items scale (GAD-7) (31.8%). Different studies used different cutoff values to determine the overall prevalence, as well as the severity of anxiety. In the random-effects model, the pooled prevalence of anxiety was 20% (95% CI: 15–25%) in the 22 studies (Figure 2A), indicating in general that 20% of the adults in Spain had anxiety symptoms during the COVID-19 pandemic. Based on a normal distribution, the prediction interval is 0–67%, which is the range of the prevalence of anxiety symptoms in comparable studies.
Table 1. Study characteristics for mental health symptoms in COVID-19 epidemic in Spain.

| Characteristics       | Total Number of Studies/Samples * | Percent (%) | Level of Analysis |
|-----------------------|----------------------------------|-------------|------------------|
| Overall               | 28/38                            | 100         | Study            |
| Design                |                                   |             |                  |
| Cohort                | 4                                | 14.29       |                  |
| Cross-sectional       | 24                               | 85.71       |                  |
| Publication status    |                                   |             |                  |
| Preprint              | 2                                | 7.14        | Study            |
| Published             | 26                               | 92.86       |                  |
| Quality               |                                   |             |                  |
| >6                    | 7                                | 25.0        | Study            |
| Between 5 and 6       | 21                               | 75.0        |                  |
| <5                    | 0                                | 0.0         |                  |
| Population            |                                   |             |                  |
| Frontline HCW         | 3                                | 7.89        | Sample           |
| General population    | 30                               | 78.95       |                  |
| Student               | 5                                | 13.16       |                  |
| Outcome #             |                                   |             | Prevalence       |
| Anxiety               | 52                               | 47.1        |                  |
| Depression            | 52                               | 47.1        |                  |
| Insomnia              | 5                                | 4.59        |                  |
| Severity #            |                                   |             | Prevalence       |
| Above mild            | 39                               | 35.78       |                  |
| Above moderate        | 30                               | 27.52       |                  |
| Severe                | 23                               | 21.1        |                  |
| Overall               | 17                               | 15.6        |                  |
| Sample size           | 1199 (2272)                      | 44–21207    | Sample           |
| Response rate         | 70.3% (73.9%)                    | 20.0–98.0%  | Sample           |
| Female portion        | 70.25% (64.7%)                   | 0–100%      |                  |

* One study may include multiple independent samples such as frontline HCWs and general population [31].
# The total prevalence of mental health outcomes is larger than the 38 samples because one sample can assess multiple mental health outcomes including anxiety, depression, and insomnia. Similarly, a study may report multiple levels of severity on each mental health outcome for each sample.

Figure 1. A PRISMA flow diagram.
Figure 2. Cont.
Figure 2. Cont.
Figure 2. (A–C). Forest plot of the prevalence of anxiety, depression and insomnia.

Figure legend: The square markers indicate the prevalence of the symptom at the different level for different populations. The size of the marker correlates to the inverse variance of the effect estimate and indicates the weight of the study. The diamond data marker indicates the pooled prevalence.

A total of 20 samples from a total of 22 articles that we reported in this meta-analysis were on depression, for a total of 82,890 respondents. The most commonly included depression instruments were used, with DASS-21 being the most popular (50%) along with Patient Health Questionnaire (PHQ)-9 (31.8%). In the random-effects model, the pooled prevalence of depression was 22% (95% CI: 18–28%) among the 22 studies (Figure 2B). Its prediction internal is 0–65% and the prevalence of insomnia symptoms in comparable studies will fall within this range.

Five samples of the three articles that we reported in this meta-analysis reported on insomnia, for a total of 745 respondents. The Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI) were used to measure insomnia. In the random-effects model, the pooled prevalence of insomnia is 57% (95% CI: 48–66%) (Figure 2C). Its prediction internal is 25–87%.

The overall prevalence of mental health symptoms in Spain’s frontline HCWs, students, and general population are 50%, 42%, and 19%, respectively. The overall prevalence rates of mental health symptoms that surpassed the cutoff values of mild, moderate, and severe symptoms were 38%, 18%, and 7%, respectively (Table 2). I² vary from 83.5% to 99.4%, similar to those in the published meta-analyses on mental health during COVID-19 [3,45–50].
Table 2. The pooled prevalence rates of mental health symptoms by subgroups of population, outcome, and severity.

| First-Level Subgroup | Second-Level Subgroup | Prevalence (%) | 95% CI       |
|----------------------|-----------------------|----------------|-------------|
|                      | Aggregated prevalence | 22%            | 18–26%      |
| Population           | Frontline HCW         | 42%            | 22–64%      |
|                      | General population    | 19%            | 16–23%      |
|                      | Student               | 50%            | 32–69%      |
| Outcome              | Anxiety               | 20%            | 15–25%      |
|                      | Depression            | 22%            | 18–28%      |
|                      | Insomnia              | 57%            | 48–66%      |
| Severity             | Above mild            | 38%            | 30–46%      |
|                      | Above moderate        | 18%            | 14–21%      |
|                      | Severe                | 7%             | 5–9%        |
|                      | Overall               | 25%            | 16–34%      |
| Quality              | Studies with high quality | 21%         | 15–27%      |
|                      | Studies with medium quality | 23%     | 19–27%      |

Note: CI = Confidence Interval.

3.4. Quality of Articles

Using the Mixed Methods Appraisal Tool (MMAT)\(^{18}\), we found that seven studies (25%) are of higher quality, 21 studies (75%) had medium quality, and 0 studies were of low quality (Table 1). The subgroup analysis suggests the studies with high quality reported lower prevalence of mental health symptoms in Spain (Table 2).

3.5. Sensitivity Analysis

Figure 3 depicts the Doi plot and a Luis Furuya–Kanamori (LFK) index of \(-0.45\), indicating ‘no asymmetry’ and the unlikely presence of publication bias. We also tested the impact of publication status and sample size and did not find significant influence.

Figure 3. Depiction of publication bias in the baseline meta-analysis of proportion studies based on Doi plot and the Luis Furuya-Kanamori (LFK) index-a score that is within ±1 indicates ‘no asymmetry’.
4. Discussion

4.1. Overview of the Findings

To date, this meta-analysis is the first to report the pooled prevalence of mental health symptoms in key populations in Spain during the COVID-19 crisis. Our study included data from 38 samples and 28 articles for a total of 86,323 adults in a single year of the COVID-19 pandemic. The pooled prevalence rates of anxiety, depression, and insomnia symptoms at the mild above level are 34%, 36%, and 52%, respectively (Table 3). The analysis found that both students and frontline HCWs had much higher prevalence rates of mental health symptoms than the general population. The foregoing finding of greater risk in students and frontline HCWs is in accordance with what has been reported elsewhere. The higher prevalence in students may be due to their tendencies to worry over the health both of themselves and loved ones as well as the pressures they face [51,52], while daily interactions in jobs with high-risk virus transmission could impact frontline HCWs [53].

Table 3. Subgroup analyses of the prevalence of anxiety, depression, and insomnia.

| Groups         | Subgroups     | Anxiety       | Depression     | Insomnia       |
|----------------|---------------|---------------|----------------|----------------|
| Number of studies | 22            | 22            | 3              |
| Number of samples | 29            | 30            | 5              |
| Total # participants | 82,024        | 82,890        | 745            |
| Aggregated prevalence | 20%, 95% CI: 15–25% | 22%, 95% CI: 18–28% | 57%, 95% CI: 48–66% |
| Population      | Frontline HCW | 46%, 95% CI: 14–80% | 33%, 95% CI: 06–69% | 57%, 95% CI: 47–66% |
|                 | General population | 17%, 95% CI: 12–22% | 20%, 95% CI: 16–25% | 55%, 95% CI: 48–61% |
|                 | Student       | 39%, 95% CI: 18–62% | 59%, 95% CI: 58–61% | 64%, 95% CI: 59–68% |
| Severity        | Above mild    | 34%, 95% CI: 20–50% | 36%, 95% CI: 29–43% | 57%, 95% CI: 48–66% |
|                 | Above moderate | 19%, 95% CI: 12–26% | 17%, 95% CI: 14–20% |                  |
|                 | Severe        | 8%, 95% CI: 5–12%  | 6%, 95% CI: 4–8%   |                  |
|                 | Overall       | 16%, 95% CI: 5–12%  | 35%, 95% CI: 28–43% |                  |
| Instrument      | DASS-21       | 15%, 95% CI: 11–20% | 21%, 95% CI: 15–28% |                  |
|                 | GAD-7/PHQ-9   | 31%, 95% CI: 17–46% | 22%, 95% CI: 13–32% |                  |

Note: 95% CI = 95% Confidence Interval. * For insomnia, all severity level is mild above in the studies we examined.

Insomnia appeared to be much more prevalent than anxiety and depression in Spain, with 57% of the population being diagnosed with insomnia. Part of the reason for this might be that all five samples on the prevalence of insomnia used a mild above severity level, yielding a higher prevalence rate.

4.2. Comparison with Prior Meta-Analyses

Given that this meta-analysis is the first on the topic in Spain, it is worthwhile to compare the findings with similar meta-analyses in other countries. Most meta-analyses on COVID-19 mental health were conducted in a few geographical regions, with the majority in China, the first country to experience the COVID-19 crisis. The pooled prevalence of anxiety symptoms in Spain’s population was 34%, which is much higher than that reported in Bareeqa et al. (2020) (22%), Pappa et al. (2020) (23%), Krishnamoorthy et al. 2020 (26%) and Ren et al. 2020 (25%) [50,54–56]. Similarly, the pooled prevalence rate for depression in Spain’s population is 35%, which is much higher than reported in Bareeqa et al. (2020) (27%), Pappa et al. (2020) (23%), Krishnamoorthy et al. 2020 (26%), and Ren et al. 2020 (28%) [50,54–56]. The prevalence rates in Spain exceed the reported prevalence rates of mental health symptoms in China, suggesting that a higher percent of people in Spain suffered greater mental health symptoms. Differences across countries may be due to differences in social determinants and exposure to media [57].

In addition, the pooled prevalence of mild above anxiety in Spain is higher than those of a meta-analysis including data collected in 10 countries (China, India, Japan, Iran,
Iraq, Italy, Nepal, Nigeria, Spain, and UK) (32%) [45] and is similar to those of another meta-analysis including data collected in 17 countries (i.e., China, Singapore, India, Japan, Pakistan, Vietnam, Iran, Israel, Italy, Spain, Turkey, Denmark Greece, Argentina, Brazil, Chile, and Mexico) (33%) [3]. The pooled prevalence for depression in Spain is also higher than those in a study of 17+ countries reported by Luo et al. [3] (28%) and higher than another study of 10 countries reported by Salari (34%) [45]; however, the prevalence rate for depression in Spain is still lower than Italy, which has the highest rate (67%) [3].

The pooled prevalence of anxiety during COVID-19 is much higher than the overall pooled prevalence rate of anxiety of people ages 65+ from nine studies in Spain before COVID-19 (11%, n = 12,577) [58].

The pooled prevalence rate for insomnia among Spain’s population (57%) is much higher than those in Germany (39%) and China (27%), as well as the pooled prevalence in 13 countries including Australia, Bahrain, Canada, Germany, Greece, Iraq, India, Mexico, and USA (36%), and is similar to Italy (55%) and France (51%), two countries with the highest prevalence rates [59].

The pooled prevalence rate of mental symptoms of the student population in Spain (50%) is higher than other meta-analyses, such as 28% on anxiety reported by Lasheras et al. [60] and 32% on anxiety, 36% on depression, and 33% on sleep disturbance reported by Deng et al. [51].

4.3. Practical Implications

The findings of this meta-analysis show that there were higher rates of anxiety, depression, and especially insomnia symptoms reported in Spain, compared to all the other countries reported apart from the nearby European countries of Italy and France. The evidence suggests the need to pay attention to the high prevalence rate of insomnia. As the literature shows that insomnia can be caused by fear of infection, quarantine, and death, required safety precautions such as masks and isolation methods can be critical [48,61]. It is also reported that extensive use of social media during COVID-19 is associated with higher rates of anxiety and insomnia-related symptoms.

The evidence from this study shows that frontline HCWs and students suffered more anxiety, depression, and insomnia symptoms than the general population, which suggests that policymakers and healthcare organizations need to prioritize frontline HCWs and students in this ongoing pandemic. Frontline HCWs are at a greater risk for mental health symptoms, which could provide the impetus for policies and strategic priorities towards building resiliency in HCWs. Protective measures, such as intercessions, self-help resources, and specified care of healthcare workers, are of the utmost importance [62]. An additional reason for prioritization is to preempt a possible rise in suicide associated with mental health issues during COVID-19 [63].

The finding that insomnia had the highest prevalence rate relative to anxiety and depression in Spain suggests a clarion call to probe populations for the presence of insomnia during the COVID-19 pandemic. It is also important to explore underlying causative factors resulting in the extraordinarily high rates. Moreover, our findings on the high rate of insomnia compared to anxiety and depression, which have been the most studied mental health symptoms, acts as a call for future research on insomnia, especially given that more than 90% of existing empirical studies studied anxiety and depression [64].

Lastly, to our surprise, no studies have examined the mental health symptoms of general HCWs in Spain. A possible reason for this could be that all general HCWs are on the frontline giving the needs of the country. More research overall is needed to investigate the prevalence in HCWs.

4.4. Limitations and Future Research

Our meta-analysis had several limitations. Among the 38 samples included in this meta-analysis, 30 samples (78.95%) investigated the prevalence of the general population in Spain with only three samples on frontline HCWs and five samples on students.
The lack of sufficient data from HCWs and students limited the reliability of the pooled prevalence rates.

Secondly, we found that articles used different instruments and inconsistent cutoff scores, which makes it difficult and often impossible to accumulate and compare research findings. For example, the prevalence of anxiety measured by GAD-7 (31%) and DASS-21 (15%), the two most popular scales, differed significantly in Spain (Table 3). Additionally, several articles reported an “overall” prevalence without indicating the cutoff points used, which makes it impossible to know which outcome level they used. We suggest that future research specifies the severity levels and the cutoff points used, especially to report overall prevalence. Third, non-English articles were not included and hence could create biases in our study.

5. Conclusions

This is the first meta-analysis to provide evidence on the pooled prevalence rates of anxiety, depression, and insomnia in Spain during the COVID-19 pandemic. Our results indicate that the people in Spain are experiencing psychological and emotional distress during COVID-19, possibly greater than in some other countries. Therefore, it is critical to identify the prevalence of specific psychological symptoms of the key populations to guide mental health assistance and resource allocation efforts in the unprecedented crisis.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/ijerph19021018/s1, Table S1. Study characteristics for mental health symptoms in COVID-19 epidemic in Spain; and Table S2. The pooled prevalence rates of mental health symptoms by subgroups of population, outcome, and severity.

Author Contributions: R.Z.C.: Investigation, Data curation, Formal analysis, Visualization, Writing—original draft, Writing—review & editing, S.X.Z.: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Data curation, Visualization, Writing—original draft, Writing—review & editing, Supervision. W.X., A.Y., R.K.D., B.Z.C., A.Y.D., S.M.: Investigation, Data curation, R.S.M., Writing—review & editing, W.Y.; fund, Writing—review & editing, X.W.: Investigation, Data curation. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Guangdong Natural Science Foundation [grant numbers 2019A1515011921]. This research received no external funding.

Institutional Review Board Statement: Ethical review and approval is not applicable to this study, due to it being a meta-analysis of existing studies.

Informed Consent Statement: Informed consent is not applicable to this study, due to it being a meta-analysis of existing studies.

Data Availability Statement: All data are available through https://www.dropbox.com/sh/5068kumz1o7iv5d/AAAKs149KGg_XjeR7wtGALO4a?dl=0 (accessed on 28 August 2021).

Conflicts of Interest: All authors have completed the Unified Competing Interest form and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

References
1. Oliver, N.; Barber, X.; Roomp, K.; Roomp, K. Assessing the Impact of the COVID-19 Pandemic in Spain: Large-Scale, Online, Self-Reported Population Survey. J. Med. Internet Res. 2020, 9, e21319. [CrossRef]
2. Benke, C.; Autenrieth, L.K.; Asselmann, E.; Pané-Farré, C.A. Lockdown, quarantine measures, and social distancing: Associations with depression, anxiety and distress at the beginning of the COVID-19 pandemic among adults from Germany. Psychiatry Res. 2020, 293, 113462. [CrossRef] [PubMed]
3. Luo, M.; Guo, L.; Yu, M.; Jiang, W.; Wang, H. The psychological and mental impact of coronavirus disease 2019 (COVID19) on medical staff and general public—A systematic review and meta-analysis. Psychiatry Res. 2020, 291, 113190. [CrossRef] [PubMed]
4. Xiong, J.; Lipsitz, O.; Nasri, F.; Lui, L.M.; Gill, H.; Phan, L.; Chen-Li, D.; Iacobucci, M.; Ho, R.; Majeed, A.; et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J. Affect. Disord. 2020, 277, 55–64. [CrossRef] [PubMed]
5. Picaza Gorrochategi, M.; Eiguren Munitis, A.; Dosil Santamaria, M.; Ozamiz Etxebarria, N. Stress, anxiety, and depression in people aged over 60 in the COVID-19 outbreak in a sample collected in Northern Spain. *Am. J. Geriatr. Psychiatry* 2020, 28, 993–998. [CrossRef]

6. Luceño-Moreno, L.; Talavera-Velasco, B.; García-Albuquerque, Y.; Martin-García, J. Symptoms of Posttraumatic Stress, Anxiety, Depression, Levels of Resilience and Burnout in Spanish Health Personnel during the COVID-19 Pandemic. *Int. J. Environ. Res. Public Health* 2020, 17, 5514. [CrossRef]

7. Chen, J.; Farah, N.; Dong, R.K.; Chen, R.Z.; Xu, W.; Yin, A.; Chen, B.Z.; Delios, A.; Miller, S.; Wan, X.; et al. The Mental Health Under the COVID-19 Crisis in Africa: A Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* 2021, 18, 10604. [CrossRef]

8. Pappa, S.; Chen, J.; Barnet, J.; Zhang, A.; Dong, R.K.; Xu, W.; Yin, A.; Chen, B.Z.; Delios, A.; Chen, R.Z.; et al. A Systematic Review and Meta-Analysis of the Mental Health Impact of the COVID-19 Pandemic in Southeast Asia. *Psychiatry Clin. Neurosci.* 2021, in press. [CrossRef]

9. Zhang, S.X.; Miller, S.O.; Xu, W.; Yin, A.; Chen, B.Z.; Delios, A.; Dong, R.K.; Chen, R.Z.; McIntyre, R.S.; Wan, X.; et al. Meta- Analytic Evidence of Depression and Anxiety in Eastern Europe during the COVID-19 Pandemic. *Eur. J. Psychiatr. Traumatol.* 2021, 34, 285–291. [CrossRef]

10. Liu, K.; Yang, B.X.; Luo, D.; Liu, Q.; Ma, S.; Huang, R.; Lu, W.; Majeed, A.; Lee, Y.; Lui, L.M.W.; et al. The Mental Health Effects of COVID-19 on Health Care Providers in China. *Am. J. Psychiatry* 2020, 117, 635–636. [CrossRef]

11. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* 2021, 372, n71.

12. Chen, X.; Chen, J.; Zhang, M.; Chen, R.Z.; Dong, R.K.; Dong, Z.; Ye, Y.; Tong, L.; Chen, B.Z.; Zhao, R.; et al. One Year of Evidence on Mental Health in China in the COVID-19 Crisis—A Systematic Review and Meta-Analysis. *Medrxiv* 2021. [CrossRef]

13. Hong, Q.N.; Pluye, P.; Fabregues, S.; Bartlett, G.; Boardman, F.; Cargo, M.; Dagenais, P.; Gagnon, M.P.; Griffiths, F.; Nicolau, B.; et al. The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. *Educ. Inf.* 2018, 34, 285–291. [CrossRef]

14. Hunter, J.P.; Saratzis, A.; Sutton, A.J.; Boucher, R.H.; Sayers, R.D.; Bowne, M.J. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. *J. Clin. Epidemiol.* 2014, 67, 897–903. [CrossRef]

15. Furuya-Kanamori, L.; Xu, C.; Lin, L.; Doan, T.; Chud, H.; Thalib, L.; Doi, S.A.R. P value—driven methods were underpowered to detect publication bias: Analysis of Cochrane review meta-analyses. *J. Clin. Epidemiol.* 2020, 118, 86–92. [CrossRef]

16. Furuya-Kanamori, L.; Barendregt, J.J.; Doo, S. A new improved graphical and quantitative method for detecting bias in meta-analysis. *Int. J. Evid. Based Healthc.* 2018, 16, 195–203. [CrossRef]

17. Fullana, M.A.; Hidalgo-Mazzei, D.; Vieta, E.; Radua, J. Coping behaviors associated with decreased anxiety and depressive symptoms during the Depression-19 pandemic and lockdown. *J. Affect. Disord.* 2020, 275, 80–81. [CrossRef]

18. Arpino, B.; Pasqualini, M.; Bordone, V.; Solé-Auró, A. Older People’s Nonphysical Contacts and Depression During the COVID-19 Lockdown. *Gerontologist* 2020, 61, 176–186. [CrossRef]

19. Bobes-Bascarán, T.; Sáiz, P.A.; Velasco, A.; Martínez-Cao, C.; Psych, C.P.; Portilla, A.; de la Fuente-Tomás, L.; García-Alvarez, L.; García-Portilla, M.P.; Bobes, J. Early Psychological Correlates Associated With COVID-19 in A Spanish Older Adult Sample. *Am. J. Geriatr. Psychiatry* 2020, 28, 1287–1298. [CrossRef]

20. Boni, R.B.D.; Balanzá-Martinez, V.; Correa, J.; Cardoso, T.D.A.; Ballester, P.; Atienza-Carbonell, B.; Bastos, F.I.; Kapczinski, F. Depression, Anxiety, and Lifestyle Among Essential Workers: A Web Survey From Brazil and Spain During the COVID-19 Pandemic. *J. Med. Internet Res.* 2020. [CrossRef]

21. Diaz-Jiménez, R.M.; Caravaca-Sánchez, F.; Martín-Cano, M.C.; Fuente-Robles, Y.M.D.L. Anxiety levels among social work students during the COVID-19 lockdown in Spain. *Soc. Work Health Care* 2020, 59, 681–693. [CrossRef] [PubMed]

22. García-Alvarez, L.; Fuente-Tomá, L.d.l.; García-Portilla, M.P. Early psychological impact of the 2019 coronavirus disease (COVID-19) pandanic and lockdown in a large Spanish sample. *J. Glob. Health* 2020, 10, 020505. [CrossRef] [PubMed]

23. García-Fernández, L.; Romero-Ferreiro, V.; López-Roldán, P.D.; Padilla, S.; Rodríguez-Jiménez, R. Mental Health in Elderly Spanish People in Times of COVID-19 Outbreak. *Am. J. Geriatr. Psychiatry* 2020, 29, 1040–1045. [CrossRef]

24. García-Portilla, P.; Tomá, L.d.l.f.; Bobes-Bascarán, T.; Treviño, L.J.; Madera, P.Z.; Álvarez, M.S.; Miranda, I.M.; Álvarez, L.G.; Martínez, P.A.S.; Bobes, J. Are older adults also at higher psychological risk from COVID-19? *Aging Ment. Health* 2020, 25, 1297–1304. [CrossRef] [PubMed]

25. Garre-Olmo, J.; Turró-Garriga, O.; Martí-Lluch, R.; Zacarías-Pons, L.; Alves-Cabratos, L.; Serrano-Sarbossa, D.; Vilalta-Franch, J.; Ramos, R. Changes in lifestyle resulting from confinement due to COVID-19 and depressive symptomatology: A cross-sectional a population-based study. *Compr. Psychiatry* 2021, 104, 152214. [CrossRef]

26. González-Sanguino, C.; Ausin, B.; Castellanos, M.A.; Saiz, J.; López-Gómez, A.; Ugidos, C.; Muñoz, M. Mental health consequences during the initial stage of the 2020 Coronavirus pandemic (COVID-19) in Spain. *Brain Behav. Immun.* 2020, 87, 172–176. [CrossRef]

27. Dosil, M.; Ozamiz-Etxebarria, N.; Redondo, I.; Picaza, M.; Jaureguizar, J. Psychological Symptoms in Health Professionals in Spain After the First Wave of the COVID-19 Pandemic. *Front. Psychol.* 2020, 11, 606121. [CrossRef] [PubMed]
28. Jacques-Aviñó, C.; López-Jiménez, T.; Medina-Perucha, L.; de Bont, J.; Gonçalves, A.Q.; Duarte-Salles, T.; Berenguera, A. Gender-based approach on the social impact and mental health in Spain during COVID-19 lockdown: A cross-sectional study. *BMJ* 2020, 10, e044617.

29. López-Bueno, R.; Calatayud, J.; Ezzatvar, Y.; Casajús, J.A.; Smith, L.; Andersen, L.L.; López-Sánchez, G.F. Association Between Current Physical Activity and Current Perceived Anxiety and Mood in the Initial Phase of COVID-19 Confinement. *Front. Psychol.* 2020, 11, 729. [CrossRef]

30. Martin, A.H.S.; Serrano, J.P.; Cambriles, T.D.; Arias, E.M.A.; Méndez, J.; del Yerro Álvarez, M.J.; Sánchez, M.G. Sleep characteristics in health workers exposed to the COVID-19 pandemic. *Sleep Med.* 2020, 75, 388–394. [CrossRef]

31. Martínez-de-Quela, Ó.; Suárez-Iglesias, D.; López-Florese, M.; Pérez, C.A. Physical activity, dietary habits and sleep quality before and during COVID-19 lockdown: A longitudinal study. *Appetite* 2021, 158, 105019. [CrossRef]

32. García-Fernández, L.; Romero-Ferreiro, V.; Padilla, S.; López-Roldán, P.D. Gender difference in emotional response to the COVID-19 outbreak in Spain. *Brain Behav.* 2021, 11, e01934. [CrossRef] [PubMed]

33. Mónica, C.O.; Maria, A.A.; Bernat-Carles, S.F.; Josefina, P.M. The Impact of COVID-19 on Spanish Health Professionals: A Description of Physical and Psychological Effects. *DiGiDi* *Int. J. Ment. Health Promot.* 2020, 22, 185–198.

34. Odriozola-González, P.; Planchuelo-Gómez, A.; Irurtia, M.J.; Luis-García, R. Psychological effects of the COVID-19 outbreak and lockdown among students of a Spanish university. *Psychiatr. Res.* 2020, 290, 113108. [CrossRef]

35. Odriozola-González, P.; Planchuelo-Gómez, A.; Irurtia-Muñoz, M.J.; Luis-García, R.d. Psychological symptoms of the outbreak of the COVID-19 crisis and confinement in the population of Spain. *J. Health Psychol.* 2020, in press. [CrossRef] [PubMed]

36. Ozamiz-Etxebarria, N.; Dosił-Santamaria, M.; Picaza-Gorrotxategui, M.; Idoia-Mondragon, N. Stress, anxiety, and depression levels in the initial stage of the COVID-19 outbreak in a population sample in the northern Spain. *SciELO* 2020, 36, 1–8.

37. Ozamiz-Etxebarria, N.; Mondragon, N.I.; Santamaria, M.D.; Gorrotxategi, M.P. Psychological Symptoms During the Two Stages of Lockdown in Response to the COVID-19 Outbreak: An Investigation in a Sample of Citizens in Northern Spain. *Front. Psychol.* 2020, 11, 1491. [CrossRef] [PubMed]

38. Ozamiz-Etxebarria, N.; Santamaria, M.D.; Munitis, A.E.; Gorrotxategi, M.P. Reduction of COVID-19 Anxiety Levels Through Relaxation Techniques: A Study Carried Out in Northern Spain on a Sample of Young University Students. *Front. Psychol.* 2020, 11, 2038. [CrossRef]

39. Ozamiz-Etxebarria, N.; Sanxo, N.B.; Mondragon, N.I.; Santamaria, M.D. The Psychological State of Teachers During the COVID-19 Crisis: The Challenge of Returning to Face-to-Face Teaching. *Front. Psychol.* 2021, in press. [CrossRef]

40. Pérez, S.; Masegoso, A.; Hernández-Espeso, N. Levels and variables associated with psychological distress during confinement due to the coronavirus pandemic: A community sample of Spanish adults. *Wiley* 2020, 28, 606–614. [CrossRef]

41. Planchuelo-Gómez, A.; Odriozola-González, P.; Irurtia, M.J.; Luis-García, R. Longitudinal evaluation of the psychological impact of the COVID-19 crisis in Spain. *J. Affect. Disord.* 2020, 277, 842–849. [CrossRef]

42. Rodríguez-Rey, R.; Garrido-Hernansáiz, H.; Collado, S. Psychological Impact and Associated Factors During the Initial Stage of the Coronavirus (COVID-19) Pandemic Among the General Population in Spain. *Front. Psychol.* 2020, 11, 1540. [CrossRef] [PubMed]

43. Romero-Blanco, C.; Rodríguez-Almagro, J.; Onieva-Zafría, M.D.; Parra-Fernández, M.L.; Prado-Laguna, M.d.C.; Hernández-Martínez, A. Sleep Pattern Changes in Nursing Students during the COVID-19 Lockdown. *Int. J. Environ. Res. Public Health* 2020, 17, 5222. [CrossRef] [PubMed]

44. Valiente, C.; Contreras, A.; Peinado, V.; Trucharte, A.; Martínez, A.P.; Vázquezdo, C. Psychological Adjustment in Spain during the COVID-19 Pandemic: Positive and Negative Mental Health Outcomes in the General Population. *Span. J. Psychol.* 2021, 24, e8. [CrossRef] [PubMed]

45. Salari, N.; Hosseini-Far, A.; Jalali, R.; Vaisi-Raygani, A.; Rasoulooor, S.; Mohammadi, M.; Rasoulooor, S.; Khaleed-Paveh, B. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: A systematic review and meta-analysis. *Glob. Health Epidemiol. Psychiatr. Sci.* 2020, 11, 5222. [CrossRef] [PubMed]

46. Zhang, S.X.; Batra, K.; Liu, T.; Dong, R.K.; Xu, W.; Yin, A.; Delios, A.Y.; Chen, B.Z.; Chen, R.Z.; Miller, S.; et al. Meta-Analytical Evidence on Mental Disorder Symptoms During the COVID-19 Pandemic in Latin America. *Epidemiol. Psychiatr. Sci.* 2021, 12, 2001192. [CrossRef]

47. Rogers, J.P.; Chesney, E.; Oliver, D.; APollak, T.; McGuire, P.; Fusar-Poli, P.; Zandi, M.S.; Lewis, G.; David, A.S. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry* 2020, 7, 611–627. [CrossRef]

48. Cénata, J.M.; Blais-Rochettea, C.; Kokou-Kpolou, C.K.; Noorishad, P.-G.; Munkuni, J.N.; McIntee, S.-E.; Dalexisc, R.D.; Goulet, M.-A.; Labelle, P.R. Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis. *Psychiatry Res.* 2021, 295, 113599. [CrossRef]

49. De Pablo, G.S.; Serrano, J.V.; Catalan, A.; Arango, C.; Moreno, C.; Ferre, F.; Shin, J.I.; Sullivan, S.; Brondino, N.; Solmi, M. Impact of coronavirus syndromes on physical and mental health of healthcare workers: Systematic review and meta-analysis. *J. Affect. Disord.* 2020, 275, 48–57. [CrossRef] [PubMed]
50. Krishnamoorthy, Y.; Nagarajan, R.; Sayaa, G.K.; Menon, V. Prevalence of psychological morbidities among general population, healthcare workers and COVID-19 patients amidst the COVID-19 pandemic: A systematic review and meta-analysis. Psychiatry Res. 2020, 293, 113382. [CrossRef] [PubMed]

51. Deng, J.; Zhou, F.; Hou, W.; Silver, Z.; Wonga, C.Y.; Chang, O.; Drakos, A.; Zuo, Q.K.; Huang, E. The prevalence of depressive symptoms, anxiety symptoms and sleep disturbance in higher education students during the COVID-19 pandemic: A systematic review and meta-analysis. Psychiatry Res. 2021, 301, 113863. [CrossRef] [PubMed]

52. Son, C.; Hegde, S.; Smith, A.; Wang, X.; Sasangohar, F. Effects of COVID-19 on College Students’ Mental Health in the United States: Interview survey study. J. Med. Internet Res. 2020, 22, e21279. [CrossRef] [PubMed]

53. Wu, T.; Jia, X.; Shi, H.; Niu, J.; Yin, X.; Xie, J.; Wang, X. Prevalence of mental health problems during the COVID-19 pandemic: A systematic review and meta-analysis. J. Affect. Disord. 2021, 281, 91–98. [CrossRef] [PubMed]

54. Bareeqa, S.B.; Ahmed, S.I.; Samar, S.S.; Yasin, W.; Zehra, S.; Monese, G.M.; Gouthro, R.V. Prevalence of depression, anxiety and stress in China during COVID-19 pandemic: A systematic review with meta-analysis. Int. J. Psychiatry Med. 2021, 56, 210–227. [CrossRef]

55. Pappa, S.; Ntella, V.; Giannakouls, V.G.; Papoutsi, E.; Katsaounou, P. Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. Brain Behav. Immun. 2020, 88, 901–907. [CrossRef]

56. Ren, X.; Huang, W.; Pan, H.; Huang, T.; Wang, X.; Ma, Y. Mental Health During the Covid-19 Outbreak in China: A Meta-Analysis. Psychiatr. Q. 2020, 91, 1033–1045. [CrossRef]

57. Wang, C.; Chudzicka-Czupala, A.; Tee, M.L.; núñez, M.I.L.; Tripp, C.; Fardin, M.A. A chain mediation model on COVID-19 symptoms and mental health outcomes in Americans, Asians and Europeans. Sci. Rep. 2021, 11, 1–12. [CrossRef]

58. Villagrasa, B.; Olaya, B.; Lopez-Anton, R.; Cámera, C.d.l.; Lobo, A.; Santabárbara, J. Prevalence of anxiety disorder among elderly adults in Spain: A meta-analysis. J. Affect. Disord. 2019, 246, 408–417. [CrossRef]

59. Jahrami, H.; BaHammam, A.S.; Bragazzi, N.L.; Saif, Z.; Faris, M.; Vitiello, M.V. Sleep problems during COVID-19 pandemic by population: A systematic review and meta-analysis. J. Clin. Sleep Med. 2020, 17, 299–313. [CrossRef]

60. Lasheras, I.; Gracia-García, P.; Lipnicki, D.M.; Bueno-Notivol, J.; López-Antón, R.; de la Cámara, C.; Lob, A.; Santabárbara, J. Prevalence of Anxiety in Medical Students during the COVID-19 Pandemic: A Rapid Systematic Review with Meta-Analysis. Int. J. Environ. Res. Public Health 2020, 17, 6603. [CrossRef]

61. Yu, B.Y.-M.; Yeung, W.-F.; Lam, J.C.-S.; Chun-SumYuen, S.; Lam, S.C.; Chi-HoChung, V.; Chung, K.-F.; Lee, P.H.; Ho, F.Y.-Y.; Ho, J.Y.-S. Prevalence of sleep disturbances during COVID-19 outbreak in an urban Chinese population: A cross-sectional study. Sleep Med. 2020, 74, 18–24. [CrossRef] [PubMed]

62. Hossain, M.; Purohit, N.; Sultan, A.; Ma, P.; Lisako, E.; McKyer, J.; Ahmed, H.U. Prevalence of mental disorders in South Asia: An umbrella review of systematic reviews and meta-analyses. Asian J. Psychiatry 2020, 51, 102041. [CrossRef] [PubMed]

63. McIntyre, R.S.; Lee, Y. Preventing suicide in the context of the COVID-19 pandemic. World Psychiatry 2020, 19, 250–251. [CrossRef] [PubMed]

64. Alnefeesi, Y.; Siegel, A.; Lui, L.M.W.; Teopiz, K.M.; Ho, R.C.M.; Lee, Y.; Nasri, F.; Gill, H.; Lin, K.; Cao, B.; et al. Impact of SARS-CoV-2 Infection on Cognitive Function: A Systematic Review. Front. Psychol. 2021, 11, 1629. [CrossRef]